Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)
Lake Street analyst Thomas Flaten maintained a Buy rating on BioLife Solutions today and set a price target of $33.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Flaten is a 5-star analyst with an average return of 18.0% and a 54.15% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Insight Molecular Diagnostics, and Harrow Health.
In addition to Lake Street, BioLife Solutions also received a Buy from TD Cowen’s Brendan Smith in a report issued yesterday. However, on October 23, TR | OpenAI – 4o reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).
Based on BioLife Solutions’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $25.42 million and a GAAP net loss of $15.84 million. In comparison, last year the company earned a revenue of $19.72 million and had a GAAP net loss of $20.72 million
Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Last month, Casdin Partners Master Fund, L.P., a Major Shareholder at BLFS sold 750,000.00 shares for a total of $21,405,000.00.
Read More on BLFS:
